{"brief_title": "Safety and Efficacy of Two Different Doses of Asacol in the Treatment of Moderately Active Ulcerative Colitis", "brief_summary": "This study is a prospective clinical study to evaluate the safety and efficacy of two different doses of Asacol for the treatment of moderately active ulcerative colitis. In addition, a new tablet formulation will be evaluated at one of the two doses.", "condition": ["Ulcerative Colitis"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["Asacol 800 mg (mesalamine)", "Asacol 400 mg (mesalamine)"], "description": ["tablets, 4.8 g/day for 6 weeks, 2 - 800 mg Asacol tablets and 2 placebo tablets 3 times daily", "tablets, 2.4 g/day for 6 weeks, 2 - 400 mg Asacol tablets and 2 placebo tablets 3 times daily"], "arm_group_label": ["Asacol 4.8 g/day", "Asacol 2.4 g/day"], "criteria": "Inclusion Criteria: - male or female between 18 and 75 years of age; - have a confirmed diagnosis of ulcerative colitis with the extent varying from proctitis to pancolitis; - currently demonstrating moderately active disease Exclusion Criteria: Patients will be excluded from admission to the study if they have/are: - a history of allergy or hypersensitivity to salicylates or aminosalicylates; - a history of extensive small bowel resection (>1/2 the length of the small intestine) causing short bowel syndrome; - current renal or hepatic disease; - participated in any drug or device clinical study within 30 days of entry; - currently enrolled in any other clinical study; - received any oral, intravenous, intramuscular, or rectally administered corticosteroids within 1 month prior to the Baseline Visit; - received any other topical rectal therapy during the week prior to the Screening Visit; - received immunomodulatory therapy including, but not limited to, 6-mercaptopurine, azathioprine, cyclosporine, or methotrexate within 3 months prior to the Baseline Visit; - received a dose of mesalamine-containing compound by any route from which more than 1.6 g/day of mesalamine was available within 1 week prior to the Screening Visit (NOTE: 4 g/day of sulfasalazine and 4.5 g/day of balsalazide are equivalent to 1.6 g/day of mesalamine); - received antibiotics, other than topical antibiotics, within 1 week prior to the Screening Visit; - received aspirin (except for cardioprotective reasons up to a maximum dose of 325 mg/day) or NSAIDs within 1 week prior to the Baseline Visit; - if female, positive pregnancy test, or lactating.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "75 Years", "healthy_volunteers": "No", "mesh_term": ["Ulcer", "Colitis, Ulcerative", "Colitis", "Mesalamine"], "id": "NCT00073021"}